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The most recent available national estimates regarding 
the frequency of breast cancer diagnosis in South 
African (SA) women indicates a 1 in 29 lifetime risk 
of developing breast cancer.[1] The incidence of breast 
cancer in SA varies by time and place, but there is 
evidence that it is becoming more common.[2] In the Western Cape 
Province (WCP), breast cancer is relatively common, accounting for 
3% of all mortality in adult women in Cape Town – a higher percentage 
than for any other cancer.[3] Breast cancer is associated with a high 
mortality rate in SA, mainly as a result of delayed diagnosis,[4] for 
reasons including limited community awareness and restricted access 
to oncology care facilities.[5] 
A small but important minority of breast cancer cases are due to 
mutations in the BRCA1 and 2 genes, often referred to as hereditary 
breast and ovarian cancer (HBOC). Genetic counselling and 
testing for women with a family history of breast cancer has been 
available for well over a decade, and guidelines exist for the genetic 
counselling and testing process.[6] HBOC has sufficient clinical and 
public health relevance that the US Preventive Services Task Force 
recommends programmes for genetic counselling and testing of 
HBOC.[7] 
In SA, diagnostic BRCA testing has been available since 2005, 
and has been facilitated by the identification of common mutations 
in the BRCA1 and 2 genes in both Afrikaner[8,9] and other local 
populations. [10] This has allowed genetic counselling and testing to be 
offered, but attempts to establish programmes for genetic counselling 
and testing have faced many challenges. These include: the relative 
complexity of the risk assessment and testing approach; limited 
financial and human resources; limited community knowledge of 
breast cancer or of the possibility of a familial cancer; and difficulty 
accessing old hospital records of family members. 
The translation of genomic research into routine practice is 
inherently complex. Its lengthy translational research process was 
described by Khoury et al.[11] in 2007. However, little is known about 
this process beyond the relatively resource-rich infrastructures in 
which it usually takes place.[12] We therefore describe a programme 
for genetic counselling and BRCA testing developed in a resource-
constrained environment, how it evolved over time and the rates of 
BRCA mutation detection and family follow-up achieved.
Materials and methods
Population 
The population of the WCP of SA is diverse, comprising several 
predominant groups. Black South Africans of mainly Xhosa ethnicity 
make up a quarter of the population, whites of Afrikaner and 
non-Afrikaner ancestry a quarter, and people of mixed ancestry 
approximately half of the population. Tygerberg Hospital provides 
tertiary-level public health services to the eastern half of the Cape 
Town metropole, as well as half of the rural population of the 
WCP, with a total referral population of roughly 2.5 million people. 
Tygerberg Hospital is a public health facility and, as such, serves the 
70% of people who do not have access to private healthcare facilities, a 
predominantly ‘working poor’ and indigent population. Women (and 
men) suspected of having breast cancer are referred to the Tygerberg 
Hospital breast cancer team from throughout the region for diagnosis 
and management.
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Genetic counselling and testing
Throughout the time period, the focus was 
on identifying and offering genetic testing 
to those assessed as being at high risk of 
HBOC. The criteria for testing had been 
developed prior to 2005 by the local breast 
surgeons in collaboration with a molecular 
genetic laboratory researching HBOC, based 
elsewhere in SA. The initial criteria for 
offering BRCA testing were that the woman 
should be a proband affected by breast cancer 
with at least one additional risk factor on 
personal or family history.
Personal risk factors included: (i) age 
<40 years; (ii) bilateral breast cancer; and 
(iii) additional ovarian cancer.
Family history factors included: (i) 1 first-
degree relative with breast or ovarian cancer; 
(ii) >1 second-degree relatives affected; and 
(iii) male breast cancer in a relative.
The process for genetic counselling and 
testing in the period of 2005 - 2009 is depicted 
in Fig. 1. The multidisciplinary breast cancer 
team, comprising surgeons and oncologists, 
primarily provided genetic counselling (both 
pre- and post-test). Due to human resource 
capacity constraints, involvement of the clinical 
geneticist was by referral only, for patients 
testing positive. The hospital did not have a 
genetic counsellor employed during this period. 
Genetic testing comprised testing for mutations 
that are relatively common in the population 
(founder mutations), including:
• 3 mutations which make up >90% of 
BRCA mutations in Afrikaners – BRCA1 
1493delC, BRCA1 2760G>T (p.Glu881X) 
and BRCA2 8162delG.[8,9] 
• the 3 mutations known to be common 
in those of Ashkenazi Jewish ancestry – 
BRCA1 185delAG, BRCA1 1493insC and 
BRCA2 6174delT. 
• a recently described mutation that has been 
found to be more common in people of 
Xhosa and mixed ancestry in the WCP 
(BRCA2 5999del4) was added to the panel 
of ‘common mutations’ in 2009.[10]
If the common mutations were excluded and 
there was a family history of breast cancer, 
the laboratory would add a protein truncation 
test for exon 11 of the BRCA1 gene and exon 
10 and 11 of the BRCA2 gene. 
The genetic counselling and testing process 
was reviewed jointly by the breast surgeons and 
clinical geneticists at the beginning of 2010 and 
altered (as depicted in Fig. 2), to increase the 
role of the clinical geneticist/genetic counsellor. 
The aim of this was to: (i) improve post-test 
counselling; (ii) ration more expensive ‘full’ 
BRCA screening tests, which had recently 
become available – these include full sequencing 
of all exons of both the BRCA1 and 2 genes, as 
well as multiplex ligation probe analysis (MLPA) 
for large rearrangements; and (iii) improve 
family communication and follow-up for BRCA-
positive cases. Thus, a clinical geneticist/genetic 
counsellor became a regular participant in the 
multidisciplinary team, reviewed all results, and 
provided post-test genetic counselling (which 
included a discussion on further testing as 
appropriate), and provided cascade screening to 
family members. 
Genetic counselling, including a three-
generation family history, was conducted 
prior to the offer of full BRCA screening, 
which was offered to women with breast 
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Fig. 1. Counselling and testing process, 2005 - 2009.
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Fig. 2. Counselling and testing process, 2010 - 2011.
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cancer who met any one of the following personal or family history 
criteria: 
• Personal risk factors: (i) breast cancer at <35 years, (ii) bilateral breast 
cancer at <70 years, and (iii) additional ovarian cancer at any age.
• Family history factors: (i) at least 1 first-degree relative with breast 
cancer at <50 years or ovarian cancer at any age, and (ii) male 
breast cancer in a relative.
Record review
A review of laboratory records was conducted for all BRCA tests 
performed in women from the time of initiation of the programme 
in 2005 until December 2011. For patients testing BRCA-positive, 
hospital records were obtained and assessed. The following data were 
obtained: BRCA tests performed and results thereof, patient’s age 
at test (which was usually performed early in the course of patient 
management), ethnic background (where available) and family history. 
Statistical analysis
Univariate analysis of categorical data was conducted using the two-
tailed Fischer exact test, and 95% confidence intervals (CIs) calculated 
using the modified Wald method.
Ethics approval
Approval for the audit was obtained from the Research Ethics Committee 
of the University of Stellenbosch (no. N10/11/381). A waiver of informed 
consent was obtained. 
Results
The number of genetic tests performed per year is described in 
Table 1. Denominator data were only available from 2008. Since then, 
there have been 1 520 patients newly diagnosed with breast cancer, of 
whom 39 (2.6%; CI 1.8% - 3.4%) tested positive for BRCA1 or BRCA2 
mutations, and 27 (1.8%; CI 1.2% - 2.6%) carried ‘common mutations’. 
The performance of the individual genetic tests in detecting BRCA 
mutations is described in Table 2. There was a slight overlap of the tests used 
in the different time periods. Of 131 protein truncation tests performed, 
125 were prior to 2010, and 80% of the probands went on to have a protein 
truncation test (125/157 probands who tested negative for common 
mutations). Prior to 2010, only 3 individuals went on to sequencing of 
selected BRCA1/2 exons. Beginning in 2010, 29 individuals received full 
sequencing rather than protein truncation testing, and if negative, went 
on to MLPA testing. This comprised 20% of the 145 probands who tested 
negative for common mutations. Variants of unknown significance were 
identified in 7/29 full sequencing cases, the majority of which were novel 
variants. The mutations detected are detailed in Table 3. Note that testing 
for the BRCA2 5999del4 mutation was introduced only in 2009.
The ethnic group distribution amongst BRCA mutation-positive 
women is described in Table 4. The proportion of mutations detected 
in the white and mixed-ancestry population group is similar; although 
considerably more mixed ancestry than white women are treated at 
the clinic (exact figures are not available since we do not maintain 
ethnicity data for the entire clinic population). Black African women 
accounted for only 10.2% of mutation-positive cases. Although this 
number appears small, it is important to note that women of black 
African (mainly Xhosa) origin accounted for only 24/302 (7.9%) 
cases tested for BRCA mutations between 2005 and 2011. 
Follow-up of family members was compared before and after 
the clinical geneticist/genetic counsellor was included in the 
multidisciplinary team. Before this time, there were 30 BRCA 
mutations detected in probands. Only 2 family members reached 
the clinical geneticist for genetic counselling, whereas a total of 4 
received BRCA testing (0.13 per proband) and 2 of these tested 
positive. Notably, following inclusion of the clinical geneticist/genetic 
counsellor, 19 probands had a positive BRCA test; 20 family members 
(1.05 per proband) received genetic counselling, all of whom consented 
to genetic testing and 6 of whom tested positive. 
Discussion
Genetic counselling and testing approach
An important starting point for our service was to focus on women 
affected with breast cancer rather than the ‘worried well’. This strategy 
arose naturally from the initial research project on genetic testing for 
hereditary breast cancer, but has proved to be important in establishing 
an ongoing role for genetic counselling and testing. It efficiently targets 
genetic counselling at those eligible for testing. It avoids targeting the 
Table 1. Female breast cancer incidence and BRCA testing by year
Year
New cases 
n
BRCA tests performed 
n (% new cases)
Positive tests 
n (% new cases)
2005 - 5 1 (20)
2006 - 33 3 (9)
2007 - 38 6 (15.8)
2008 338 37 (11) 5 (13.5)
2009 367 60 (16.3) 15 (25)
2010 368 58 (15.8) 8 (13.8)
2011 447 71 (15.9) 11 (15.5)
Total, N (%) 1 520* 226*/302 39*/49 (16.2)
*Since 2008.
Table 2. BRCA tests and detection rates from 2005 - 2011
Genetic test
Individuals tested
n
Individuals testing positive
n (%) 95% CI
First line 
Targeted analysis for common mutations 302 36 (11.9) 8.7 - 16.1
Second line 
Protein truncation test of exon 10/11 131 9 (6.9) 3.2 - 12.6
Full sequencing of BRCA1/2 genes 29 4 (13.8) -
MLPA for rearrangements of BRCA1/2 genes 25 0 (0) -
Total, N (%) 302 49 (16.2) -
CI = confidence interval; MLPA = multiplex ligation probe analysis.
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worried well, which is wasteful, given the 
current low level of awareness of familial breast 
cancer in our community and the difficulties in 
tracing affected family members. 
Implementation of genetic testing has also 
been facilitated by a stepwise approach to testing, 
in which consent is initially obtained only for 
testing of common mutations. This step is 
relatively inexpensive and provides results that 
are easy to interpret. Initial pre-test counselling is 
provided by a primary care professional (surgery 
or oncology staff members) early in the course 
of treatment for breast cancer, using a checklist 
to determine eligibility for testing. The need for 
this approach arose as a direct consequence of the 
scarcity of genetics-trained professionals in our 
local environment. 
The use of simple criteria to identify 
women eligible for the initial offer of testing 
has facilitated its implementation, and is 
appropriate in our setting because:
• the relatively low cost of common mutation 
testing makes it possible to offer it to a 
broader group of women 
• more sophisticated scoring systems designed 
to estimate the likelihood of BRCA carrier 
status[13] are cumbersome and of uncertain 
relevance in our patient population 
• family history information is often limited. 
Because the concept of cancer is unfamiliar 
to many patients, communication 
between family members may not include 
the cause of death of relatives, and may 
not permit identification of the particular 
cancer causing the death. 
Involvement of the primary care staff in the 
counselling process maintains their stake in the 
genetic counselling and testing programme, 
and is consistent with a multidisciplinary team 
approach. Initiation of counselling and testing 
by a primary care professional is aimed at 
maximising access to genetic testing, and has 
resulted in 14.9% uptake of common mutation 
testing (since 2008: 226/1  520 breast cancer 
cases were tested). We were unable to find 
information on the proportion of breast cancer 
patients receiving BRCA testing in other 
populations, but feel that our apparently high 
rate of common mutation testing is justified 
by its relatively low cost and an acceptable 
mutation detection rate of 11.9%. 
Concerns have been raised regarding 
the appropriateness of genetic counselling 
and testing being performed shortly after 
diagnosis, in view of the potential psychosocial 
consequences.[14] However, this concern is miti-
gated by accumulating evidence of the benefit 
of tailoring surgery and adjuvant chemotherapy 
according to mutation status. [15] Treatment-
focused genetic testing is used in women newly 
diagnosed with cancer to provide them, as well 
as their managing clinicians, with important 
information on which treatment decisions can 
be based.[16] It is also used in our setting for 
reducing the cost and discomfort of recurrent 
surgeries. A recent study found that the benefits 
of knowing one’s BRCA mutation status early 
outweighed the potential psychosocial harms 
caused by learning this result shortly after being 
diagnosed.[16] 
Another reason for initiating BRCA 
testing early in the course of treatment is 
the fact that breast cancer has a relatively 
poor prognosis in our setting (as in many 
developing countries), particularly for 
younger women,[17] who are most likely to 
be eligible for testing. If BRCA testing is not 
considered timeously, the opportunity may 
be lost altogether. Although testing in these 
circumstances may not be to the benefit of the 
affected individual, it is important to be aware 
of the unaffected family members’ interest in 
genetic information.[15]
As capacity for genetic counselling 
improved over time, we chose to prioritise 
genetic counsellor involvement in post-test 
counselling for common mutation testing, 
which included decision-making regarding 
‘full’ BRCA screening. This step involves more 
complex information, more expensive testing, 
and the feedback of potentially difficult results. 
The implementation of post-test counselling 
by a genetic counsellor has allowed us to review 
whether any harm has arisen from the initial 
offer of testing occurring early in the course 
of disease by a primary care professional. Our 
experience is that there have not been any 
obvious adverse effects to date, at least when 
this approach is accompanied by detailed post-
Table 3. Description of BRCA mutations detected
Genetic test Mutation
Mutations detected
n (%)
First line
Targeted mutation analysis BRCA2 8162delG 17 (34.7)
BRCA2 5999del4 7 (14.3)
BRCA1 p.E881X 7 (14.3)
BRCA1 185delAG 2 (4.1)
BRCA1 1493delC 2 (4.1)
BRCA1 5383insC 1 (2.0)
BRCA2 6174delT 0 (0.0)
Total 36 (73.5)
Second line
Protein truncation test of exon 10/11 BRCA1 4 (8.2)
BRCA2 5 (10.2)
Sequencing BRCA1 2 (4.1)
BRCA2 2 (4.1)
MLPA 0 (0.0)
Total 13 (26.5)
BRCA1, N (%; CI) 18 (36.7; 23.4 - 51.7)
BRCA2, N (%; CI) 31 (63.3; 48.3 - 76.6)
Total, N (%) 49 (100)
MLPA = multiplex ligation probe analysis; CI = confidence interval.
Table 4. Ethnic group distribution amongst BRCA mutation-positive women
Ancestry
Mutation-positive
n (% of total mutations)
Common mutations
n (% of total mutations in ethnic group)
White (mainly Afrikaner) 21 (42.9) 18 (85.7)
Mixed ancestry 23 (46.9) 14 (60.9)
African 5 (10.2) 4 (80)
Total, N 49 36 
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test counselling by a genetic counsellor. Importantly, as both the genetic 
counselling capacity has improved and with integration of the counsellor 
within the multidisciplinary team, it has been possible to increase pre-
test counselling provided by the genetic counsellor.
Until post-test counselling was routinely provided by a genetic 
counsellor, cascade testing proved very difficult to implement. Improved 
access to a genetic counsellor has resulted in greater numbers of family 
members presenting for genetic counselling, and they appear to be a 
self-selected group who all want genetic testing. Depending on their 
place of residence, family members may present themselves to another 
breast cancer service in Cape Town or further afield, but we are not 
able to ascertain these numbers. Family members found to carry BRCA 
mutations are referred for discussion of management and surveillance 
options. At this stage we have not assessed how family members have 
used the knowledge of their BRCA status.
BRCA mutation detection rates
The relatively high detection rate for common mutations in our clinic 
(representing 1.8% of all women with breast cancer, 11.9% of those 
tested, and 73% of all mutations detected) underlines the value of first 
testing for these mutations. Although we serve an ethnically diverse 
population, common mutations exist in at least 2 large groups of 
patients – Afrikaners and black South Africans of Xhosa ethnicity – 
while common mutations from both groups occur in those of mixed 
ancestry. 
For practical reasons, testing for ‘common mutations’ includes a 
standard panel of mutations, irrespective of the patient’s ancestry. This 
panel has enlarged over time from 3 mutations to 7 mutations as new 
information has become available; it is possible that further mutations 
will be added as knowledge increases regarding the BRCA variants 
in black and mixed-ancestry South Africans. Two disease-causing 
variants in the BRCA2 gene (the BRCA2 8162delG, and the BRCA2 
5999del4 mutations) are very common and result in considerably 
more BRCA2-positive individuals being diagnosed than BRCA1 in our 
patient population, the reverse of the situation described in Western 
populations. The relatively small number of black African women tested 
reflects the current relatively low prevalence of breast cancer in this 
group, as well as the fact that BRCA testing in this group became more 
relevant following the inclusion of the BRCA2 5999del4 mutation in the 
common mutation panel after 2009.
Further analysis by protein truncation testing of large exons, 
as applied in our programme, had a relatively low detection rate. 
Although more costly, and therefore used more sparingly, sequencing 
of the BRCA genes appears to have a relatively good detection rate and 
added significantly to the targeted analysis for common mutations. 
Given the difference in cost of the 2 methods, the cost-effectiveness of 
the 2 approaches may be similar. Among 25 patients receiving MLPA 
testing, no large genetic rearrangements were detected. Variants of 
unknown significance were identified in a high proportion of cases 
receiving full sequencing (7/29; 24%), posing a significant counselling 
challenge. Further characterisation of these variants should be an 
important area of research in our population in the future.
Extrapolating back to the population of breast cancer patients, we 
found an overall rate of BRCA mutations of 2.6%. This represents a 
minimum prevalence given the targeted rather than comprehensive 
testing strategy we used. Although there is considerable variation in 
the frequency of BRCA mutations between different populations, our 
detection rate is comparable with rates determined in comprehensive 
research studies in some Western populations.[18] This suggests that 
either our testing programme detects a high proportion of all BRCA 
mutations or, more likely, that the rate of BRCA positivity is high in 
all or part of the population we serve as a result of founder effects. 
Recommendations for future research 
The impact of receiving pre-test counselling for founder mutations 
from a primary care staff member, rather than a genetic counsellor, 
requires formal investigation. Further studies should also determine 
how knowledge of BRCA status has been used in family members 
found to have a BRCA1 or 2 mutation. 
Study limitation
The study comprised a retrospective analysis of a relatively limited 
number of available data fields. However, by restricting the number 
of data fields we were able to ensure that all information was available 
for almost all patients. Although our approach may be generalisable, 
it should be noted that the utility of common mutation testing might 
vary in different parts of SA. 
Conclusions
Breast cancer genetic counselling programmes to stratify patients for 
possible genetic testing are difficult to implement in the SA environment, 
due to resource limitations and other challenges. A limited number 
of mutations are common in subsets of our diverse population, with 
overlaps in patients of mixed ancestry. This reality has facilitated genetic 
counselling and testing. The programme has also been facilitated by a 
pragmatic approach, with pre-test counselling for common mutation 
testing being undertaken by a member of the breast cancer team 
relatively soon after diagnosis, and post-test counselling being provided 
by a clinical geneticist or genetic counsellor to ensure that patients are 
appropriately informed. Family follow-up has increased considerably 
with the involvement of a genetic counsellor. 
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